Section
Paid Wall Street Wire reports.
Wound care is becoming one of big medtech's next frontiers, and Swedish wound-care leader Mölnlycke just announced a separation into an independent wound-care company. At the center of that landscape sits MediWound (NASDAQ: MDWD).
A fresh Phase 3 success at Bristol Myers puts alpha radiation back in focus. Alpha Tau is testing a different way to deliver it, with pivotal skin-cancer results approaching and a U.S. commercial partner already on board.
KRAS sat on the undruggable list for decades. Silexion's SIL204 is built to silence the mutation earlier in the cell, and the Phase 2/3 program is now moving into patients.
After encouraging early pancreatic data, demand for Alpha DaRT helped quadruple its IMPACT study from 12 patients to 48 as the company moves toward a pivotal trial.